Patient Square Capital’s Xenon Pharmaceuticals XENE Stock Holding History

Patient Square Capital’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.3M	Sell	220,000 -7,000	-3%	-$389K	2.06%	12
2026 Q1	$13.2M	Buy	227,000 +90,500	+66%	+$4.17M	2.34%	13
2025 Q4	$6.12M	Buy	+136,500	New	+$5.73M	1.31%	17

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Patient Square Capital's XENE Position: Q2 2026 in Review

Patient Square Capital reduced its Xenon Pharmaceuticals (XENE) stake by 3.1% in Q2 2026, selling an estimated $389K and leaving 220,000 shares worth $13.3M. The position accounts for 2.06% of the portfolio, ranked #12.

Patient Square Capital first reported a position in XENE in Q4 2025 and has held it in 3 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Patient Square Capital held 220,000 shares of Xenon Pharmaceuticals worth $13.3M as of Q2 2026.
Patient Square Capital sold 7,000 Xenon Pharmaceuticals shares in Q2 2026, an estimated $389K.
Xenon Pharmaceuticals made up 2.06% of Patient Square Capital's portfolio in Q2 2026, its #12 holding.
Patient Square Capital first reported a position in Xenon Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Patient Square Capital's 13F filing for Q2 2026, filed 12 Aug 2026.